MedPath

Prolene Versus Ethibond for Cervical Cerclage

Not Applicable
Completed
Conditions
Cervical Incompetence
Interventions
Other: Ethibond Suture
Other: Prolene Suture
Registration Number
NCT03311867
Lead Sponsor
Rutgers University
Brief Summary

The purpose of the proposed study is to examine the relationship between cerclage suture material of Ethibond and Prolene and its effect on the vaginal microbiome in a prospective randomized control trial. Ethibond is another commonly used suture material for performing cervical cerclage that shares some characteristics with previously studied suture materials. It is braided like the Mersilene, but thinner like the monofilament Prolene. The investigators will study whether Ethibond causes the vaginal microbiome to be adversely affected like Mersilene or whether there is a healthy microbiome like Prolene. This study will allow the investigators to determine whether it is advisable to continue to use Ethibond for cervical cerclage in clinical practice, or whether obstetricians should avoid its use as now done with Mersilene.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
16
Inclusion Criteria
  • Greater than18 years of age
  • Singleton pregnancy
  • History of preterm delivery between 17 0/7 weeks - 33 4/7 weeks with painless cervical

dilation or cervical insufficiency

Exclusion Criteria
  • younger than 18 years of age
  • multiple gestation
  • iatrogenic preterm delivery
  • pregnancies with fetal anomalies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Braided SutureEthibond SuturePatient in this group will have a cerclage with ethibond suture material
Non- Braided SutureProlene SuturePatient in this group will have a cerclage with prolene suture material
Primary Outcome Measures
NameTimeMethod
Change in Vaginal MicrobiomeAt time of cerclage placement (11-14 wks gestation) and cerclage removal (35-36 weeks gestation)

16S rRNA gene sequencing will be performed

Change in Vaginal Cytokine ExpressionAt time of cerclage placement (11-14 wks gestation) and cerclage removal (35-36 weeks gestation)

Cytokine analysis will be performed

Secondary Outcome Measures
NameTimeMethod
Rate of preterm birthDelivery between 24-26 weeks gestation

The investigators will follow patients through their pregnancy and observe if suture material is related to increased preterm birth

Trial Locations

Locations (2)

Division of Maternal Fetal Medicine

🇺🇸

New Brunswick, New Jersey, United States

High Risk Obstetrics Clinic

🇺🇸

New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath